Rate My Professor Allison Steigler

Steigler has co-authored over 80 publications, accumulating more than 3,165 citations as per ResearchGate metrics. Key contributions include the TROG 03.04 RADAR trial, where she analyzed 10-year outcomes comparing short-term versus intermediate-term ADT with radiotherapy, with or without zoledronic acid, demonstrating effects on distant recurrence-free survival and prostate cancer-specific mortality (The Lancet Oncology, 2019). Other significant papers are 'Optimal Duration of Androgen Deprivation Therapy With Definitive Radiotherapy for Localized Prostate Cancer' (JAMA Oncology, 2025), assessing ADT length's impact on metastasis-free survival; 'Perineural invasion by prostate adenocarcinoma in needle biopsies predicts bone metastasis: Ten-year data from the TROG 03.04 RADAR Trial' (Histopathology, 2020); 'CCL2/CCR2 Expression in Locally Advanced Prostate Cancer and Patient Long-Term Outcome: 10-Year Results from the TROG 03.04 RADAR Trial' (Cancers, 2024); 'Risk Stratification after Biochemical Failure following Curative Treatment of Locally Advanced Prostate Cancer: Data from the TROG 96.01 Trial' (Prostate Cancer, 2012); and analyses of PSA kinetics as prognostic tools (The Lancet Oncology, 2008). Her rigorous statistical evaluations have advanced understanding of treatment quality, organ-at-risk doses, and biological markers, informing radiation oncology guidelines and patient management strategies.